Risky endeavours for biosimilars market
European Pharmaceutical Review | August 09, 2017
To date, most biosimilars have only had moderate success; however, there are new drugs quickly coming through the pipeline which look to considerably shake up the pharmaceutical market. One of the key factors to explain why biosimilars have only seen moderate success to date is price. While traditional generics come into the market at a considerably lower price point (up to 80% less) than the branded product, biosimilars have commonly been priced with a more marginal discount – sometimes as low as 10-15%.